South Korea · Delayed Price · Currency is KRW Hanall Biopharma Statistics
Total Valuation
KRX:009420 has a market cap or net worth of KRW 2.94 trillion. The enterprise value is 2.95 trillion.
| Market Cap | 2.94T |
| Enterprise Value | 2.95T |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:009420 has 50.78 million shares outstanding. The number of shares has increased by 1.08% in one year.
| Current Share Class | 50.78M |
| Shares Outstanding | 50.78M |
| Shares Change (YoY) | +1.08% |
| Shares Change (QoQ) | +8.31% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 14.48% |
| Float | 34.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 3,161.52 |
| PS Ratio | 18.48 |
| PB Ratio | 18.11 |
| P/TBV Ratio | 30.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -580.75 |
| EV / Sales | 18.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1,414.55 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.60 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 14.16 |
| Debt / FCF | -21.21 |
| Interest Coverage | -0.76 |
Financial Efficiency
Return on equity (ROE) is -3.16% and return on invested capital (ROIC) is -0.22%.
| Return on Equity (ROE) | -3.16% |
| Return on Assets (ROA) | -0.11% |
| Return on Invested Capital (ROIC) | -0.22% |
| Return on Capital Employed (ROCE) | -0.21% |
| Weighted Average Cost of Capital (WACC) | 8.46% |
| Revenue Per Employee | 523.24M |
| Profits Per Employee | -16.70M |
| Employee Count | 304 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | -125.56M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.53% in the last 52 weeks. The beta is 0.79, so KRX:009420's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +132.53% |
| 50-Day Moving Average | 51,137.00 |
| 200-Day Moving Average | 45,128.75 |
| Relative Strength Index (RSI) | 55.97 |
| Average Volume (20 Days) | 684,297 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:009420 had revenue of KRW 159.06 billion and -5.08 billion in losses. Loss per share was -98.46.
| Revenue | 159.06B |
| Gross Profit | 82.89B |
| Operating Income | -378.22M |
| Pretax Income | -5.20B |
| Net Income | -5.08B |
| EBITDA | 3.12B |
| EBIT | -378.22M |
| Loss Per Share | -98.46 |
Balance Sheet
The company has 36.16 billion in cash and 44.20 billion in debt, with a net cash position of -8.04 billion or -158.29 per share.
| Cash & Cash Equivalents | 36.16B |
| Total Debt | 44.20B |
| Net Cash | -8.04B |
| Net Cash Per Share | -158.29 |
| Equity (Book Value) | 162.36B |
| Book Value Per Share | 2,951.90 |
| Working Capital | 38.25B |
Cash Flow
In the last 12 months, operating cash flow was -732.36 million and capital expenditures -1.35 billion, giving a free cash flow of -2.08 billion.
| Operating Cash Flow | -732.36M |
| Capital Expenditures | -1.35B |
| Depreciation & Amortization | 3.50B |
| Net Borrowing | 42.05B |
| Free Cash Flow | -2.08B |
| FCF Per Share | -41.04 |
Margins
Gross margin is 52.11%, with operating and profit margins of -0.24% and -3.19%.
| Gross Margin | 52.11% |
| Operating Margin | -0.24% |
| Pretax Margin | -3.27% |
| Profit Margin | -3.19% |
| EBITDA Margin | 1.96% |
| EBIT Margin | -0.24% |
| FCF Margin | n/a |
Dividends & Yields
KRX:009420 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.08% |
| Shareholder Yield | -1.08% |
| Earnings Yield | -0.17% |
| FCF Yield | -0.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for KRX:009420 is 90,000.00, which is 78.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 90,000.00 |
| Price Target Difference | 78.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 13.42% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.
| Last Split Date | Apr 28, 2006 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
KRX:009420 has an Altman Z-Score of 15.02 and a Piotroski F-Score of 2.
| Altman Z-Score | 15.02 |
| Piotroski F-Score | 2 |